2023-06-15 17:50:43 ET
- Dairy and beef cattle health company ImmuCell ( NASDAQ: ICCC ) said Thursday it expects to resolve its contamination problem and anticipates resuming full production for the second half of 2023 and beyond.
- The company said its goal was to produce about $6 million worth of product every quarter.
- ICCC also announced the approval by Gorham Savings Bank (GSB) and the Finance Authority of Maine (FAME) of the principal terms of a $3M debt facility.
- The debt facility is expected to consist of a $2M loan underwritten by GSB and partially insured by FAME, and a $1M direct loan from FAME.
- Press Release.
For further details see:
ImmuCell expects to resume full production in H2 2023